Related Experiment Video
Updated: Aug 20, 2025
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
Xinyu Wu1, Sandro Matosevic1,2
1Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive RHPH 112E, West Lafayette, IN 47907, USA.
Abstract:
Treatment of many cancers, particularly those that remain difficult to treat or are refractive after standard-of-care therapies, has been challenging with cell-based therapies. Although relatively safe as allogeneic therapies and innately effective against cancers without the need for antigen sensitization, natural killer (NK) cells have necessitated use of genetic manipulation approaches to enhance their specificity, persistence, and homing. Chimeric antigen receptor (CAR) and gene-edited NK cell therapies have emerged as a potent treatment modality, addressing many of the issues that have plagued such gene-based therapies with other cell types. Early examples of engineered NK cell therapies have largely leveraged their activity against hematological malignancies in combination with conventional construct architectures or by editing putative genetic targets of immunosuppression. As the motivation to tackle more complex solid tumors grows, so has the sophistication and emergence of NK-specific constructs and engineering approaches. Multi-CARs, combinations with diverse genome editing technologies, as well as responsive and sensing CARs have appeared in the context of NK cell therapy. Here we discuss engineering approaches for NK cell therapy, the latest developments in the field, and what stands in the way of those promises en route to clinical translation.
Insights
Engineered natural killer (NK) cell therapies show promise for difficult-to-treat cancers. Advanced strategies like Chimeric Antigen Receptor (CAR) NK cells are improving specificity and effectiveness for solid tumors.
Area of Science:
- Immunology
- Oncology
- Cell Therapy
Background:
- Cell-based therapies face challenges in treating refractory cancers.
- Natural Killer (NK) cells offer safety and innate anti-cancer activity but require genetic enhancement for optimal efficacy.
- Existing gene-based therapies have limitations, particularly for solid tumors.
Purpose of the Study:
- To review engineering approaches for Natural Killer (NK) cell therapy.
- To discuss recent advancements in NK cell-based cancer treatment.
- To identify barriers to the clinical translation of engineered NK cell therapies.
Main Methods:
- Review of current literature on engineered NK cell therapies.
- Analysis of Chimeric Antigen Receptor (CAR) and gene-editing technologies in NK cells.
- Discussion of novel constructs and engineering strategies for solid tumor treatment.
Main Results:
- Engineered NK cells, including CAR-NK cells, are emerging as potent treatments for hematological malignancies.
- Advanced engineering approaches are being developed to enhance NK cell efficacy against solid tumors.
- Sophisticated constructs like multi-CARs and responsive CARs are being explored.
Conclusions:
- Engineered NK cell therapy holds significant potential for treating challenging cancers.
- Continued innovation in NK cell engineering is crucial for overcoming limitations in specificity, persistence, and homing.
- Addressing challenges in clinical translation is key to realizing the full therapeutic promise of NK cell-based treatments.
Related Concept Videos
00:49What is Genetic Engineering?
00:59Gene Therapy
01:27Tumor Immunotherapy